Enfusion/ENFN

$8.67

0%
-
1D1W1MYTD1YMAX

About Enfusion

Enfusion, Inc. is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. The products and services that comprise its solution are designed to enable investment managers to take investment decisions in real-time. Its solution comprises systems integrated with a suite of technology-powered, managed services, serves the full investment lifecycle, and drives insights into and control over the business activities of the investment manager and investment operations. Its solutions end-to-end functionality includes Portfolio Management System (PMS), Order and Execution Management System (OEMS), Accounting/General Ledger System and Enfusion Analytics System. PMS is able to construct and re-balance investment portfolios, this system generates a real-time investment book of record. Intertwined with its PMS, the OEMS module offers portfolio managers, traders, compliance teams and analysts the ability to electronically communicate trade orders.

Ticker

ENFN

Sector

Technology

Trading on

NYSE

Industry

Software & Programming

CEO

Oleg Movchan

Employees

1,006

Headquarters

Chicago, United States

Website

-

Enfusion Metrics

BasicAdvanced
$1.11B
Market cap
124.84
P/E ratio
$0.07
EPS
-
Beta
-
Dividend rate

What the Analysts think about Enfusion

Analyst Ratings

Majority rating from 8 analysts.
Hold

Price Targets

Average projection from 6 analysts.
12.92% upside
High $12.00
Low $8.00
$8.67
Current price
$9.79
Average price target

Enfusion Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
4.06% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$44.3M
3.75%
Net income
$1.8M
200%
Profit margin
4.06%
190%

Enfusion Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 12.5%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.04
$0.02
$0.04
$0.04
-
Expected
$0.03
$0.03
$0.04
$0.05
$0.05
Surprise
36.37%
-27.08%
-4.11%
-12.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Enfusion stock

Buy or sell Enfusion stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing